Signature(s)
Summary sheet
- Credit lines - Credit lines
The project will support financing of eligible investments promoted by small and medium sized enterprises (SMEs) and midcaps in Italy, with particular focus on those affected by the COVID-19 crisis.
The aim is to enhance access to finance for small/medium projects carried out by SMEs and midcaps, also in the form of networks.
Final beneficiaries will be requested to comply with applicable national and EU legislation, as appropriate.
Final beneficiaries will be requested to comply with applicable national and EU legislation, as appropriate.
n/a
News & Stories
Inside the project
How and Why
A rapid response
Why
- Italy was the hardest hit country in the European Union in terms of COVID-19 death toll
- To provide a rapid response to give small businesses liquidity to tackle the crisis
How
- Casse Depositi e Prestiti provides liquidity lines to its bank partners for on-lending to small and medium sized corporates
- The loans made under this programme provide companies with working capital, when their regular business has dried up in pandemic lockdowns
Sectors & Countries
Play video
2:03
"We are standing shoulder to shoulder with Italian small businesses and microbusinesses."
Related media
Squeezing fashion out of an orange
A true by women, for women fund
Related projects and stories
Ilunion boosts environmental performance with EIB Advisory support
Spanish company saves on energy and water with EU advice, increasing its profits and the social impact of employing disabled people
Small businesses on the front lines of security
How EIB Group financing, funds and bank partnerships unlock growth for Europe’s defence SMEs, boosting innovation, resilience and security across the EU
European Commission and EIB Group announce new initiative to mobilise €10 billion investment for Europe’s biotech sector
The European Commission and the European Investment Bank (EIB) Group have today announced an initiative to mobilise €10 billion in investment in 2026-27 into the biotech and life sciences sector.